Rogacev Kyrill S, Pickering John W, Seiler Sarah, Zawada Adam M, Emrich Insa, Fliser Danilo, Heine Gunnar H
Department of Internal Medicine IV, Nephrology and Hypertension, Saarland University Medical Centre, Homburg, Germany.
Nephrol Dial Transplant. 2014 Feb;29(2):348-55. doi: 10.1093/ndt/gft422. Epub 2013 Oct 28.
The recently introduced CKD-EPIcreat-cys equation surpassed creatinine-based equations for GFR estimation in a large cross-sectional analysis. However, its performance to predict individual risk of CKD progression and death in patients with various underlying CKD etiologies is unknown.
We recruited 444 patients with CKD GFR categories 2-4 (eGFR 15-89 mL/min/1.73 m2); baseline eGFR was estimated by the established MDRD and CKD-EPIcreat equations and by the novel CKD-EPIcreat-cys equation.
Patients were followed for 2.7±1.2 years for the occurrence of the combined predefined endpoint event: death, need for renal replacement therapy or halving of eGFR. The endpoint occurred in 62 patients. Reclassification from MDRD determined categories to CKD-EPIcreat-cys categories yielded net reclassification improvements for those with the endpoint event (NRIevents) of 27.4% (95% CI: 16.7-40.0%) and for those without the event (NRInon-events) of -3.1% (-8.2 to 1.6%). Similarly, reclassification from CKD-EPIcreat categories to CKD-EPIcreat-cys categories yielded an NRIevents of 22.6% (10.2-34.3%) and NRInon-events of -11.3% (-15.9 to -6.5%). Addition of albuminuria to each eGFR equation increased the calculated risk of the outcome for a net 26-32% of those who subsequently reached the endpoint, and reduced the calculated risk in a net 21-23% in non-event patients, but only minimally.
The CKD-EPIcreat-cys equation assigned patients who went on to have the event to more appropriate CKD risk categories than MDRD and CKD-EPIcreat, but patients without the event to less appropriate categories than CKD-EPIcreat. Addition of albuminuria marginally improved risk classification for those who had the event.
在一项大型横断面分析中,最近推出的CKD-EPI肌酐-胱抑素方程在估算肾小球滤过率(GFR)方面优于基于肌酐的方程。然而,其在预测各种潜在慢性肾脏病(CKD)病因患者个体的CKD进展风险和死亡风险方面的表现尚不清楚。
我们招募了444例CKD GFR分级为2-4级(估算肾小球滤过率[eGFR]为15-89 mL/min/1.73 m²)的患者;通过已确立的MDRD方程和CKD-EPI肌酐方程以及新的CKD-EPI肌酐-胱抑素方程估算基线eGFR。
对患者随访2.7±1.2年,观察复合预定义终点事件的发生情况:死亡、需要肾脏替代治疗或eGFR减半。62例患者发生了该终点事件。从MDRD确定的分级重新分类为CKD-EPI肌酐-胱抑素分级,对于发生终点事件的患者,净重新分类改善(NRI事件)为27.4%(95%置信区间:16.7-40.0%),对于未发生事件的患者,净重新分类改善(NRI非事件)为-3.1%(-8.2至1.6%)。同样,从CKD-EPI肌酐分级重新分类为CKD-EPI肌酐-胱抑素分级,NRI事件为22.6%(10.2-34.3%),NRI非事件为-11.3%(-15.9至-6.5%)。在每个eGFR方程中加入蛋白尿,对于随后达到终点的患者,净26-32%的患者计算出的结局风险增加,对于未发生事件的患者,净21-23%的患者计算出的风险降低,但幅度很小。
与MDRD和CKD-EPI肌酐相比,CKD-EPI肌酐-胱抑素方程将发生终点事件的患者归入更合适的CKD风险分级,但将未发生事件的患者归入不如CKD-EPI肌酐合适的分级。加入蛋白尿对发生终点事件的患者的风险分类有轻微改善。